Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Early Intervention, Educational 5Radiotherapy 4Psychiatric Rehabilitation 4Capecitabine 4pembrolizumab 3Trastuzumab 3Methods 3Magnetic Resonance Spectroscopy 3Irinotecan 3Gemcitabine 3Counseling 3trametinib 2palbociclib 2cediranib 2Standard of Care 2Mental Status and Dementia Tests 2Fluorodeoxyglucose F18 2Docetaxel 2Cyclophosphamide 2Biopsy 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2veliparib 1ulixertinib 1trastuzumab biosimilar HLX02 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1relatlimab 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Dalteparin × Breast × Clear all
NCT00003674 2016-07-13

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Completed
141 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡